{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:05:47Z","timestamp":1791986747951,"version":"4.4.0"},"publisher-location":"Cham","reference-count":184,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032069474","type":"print"},{"value":"9783032069481","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-06948-1_5","type":"book-chapter","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T01:08:09Z","timestamp":1767316089000},"page":"123-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Potential of Noncoding RNAs-siRNAs in Cancer Research and Therapy: Challenges and Solutions"],"prefix":"10.1007","author":[{"family":"Himanshu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudasir","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moien","family":"Lone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"5_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"4","key":"5_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657\u2013685. https:\/\/doi.org\/10.1128\/MMBR.67.4.657-685.2003. PMID: 14665679; PMCID: PMC309050","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"5_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4161\/auto.6083","volume":"4","author":"U Akar","year":"2008","unstructured":"Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B (2008) Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 4(5):669\u2013679. https:\/\/doi.org\/10.4161\/auto.6083. Epub 2008 Apr 10. PMID: 18424910","journal-title":"Autophagy"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"S Ali Zaidi","year":"2023","unstructured":"Ali Zaidi S, Fatima F, Ali Zaidi S et al (2023) Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnol 21:381","journal-title":"J Nanobiotechnol"},{"key":"5_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"W Alshaer","year":"2021","unstructured":"Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MMM et al (2021) siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol 905:174178","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"5_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917\u2013921","journal-title":"Nat Med"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","volume":"18","author":"E Anastasiadou","year":"2018","unstructured":"Anastasiadou E, Jacob LS, Slack FJ (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5\u201318","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153688","volume":"7","author":"H Asimgil","year":"2022","unstructured":"Asimgil H, Ertetik U, \u00c7evik NC, Ekizce M, Do\u011fru\u00f6z A, G\u00f6kalp M, Ar\u0131k-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE (2022) Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 7(1):e153688. https:\/\/doi.org\/10.1172\/jci.insight.153688. PMID: 35014625; PMCID: PMC8765045","journal-title":"JCI Insight"},{"key":"5_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100645","volume":"46","author":"YG Assaraf","year":"2019","unstructured":"Assaraf YG, Brozovic A, Goncalves AC et al (2019) The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat 46:100645","journal-title":"Drug Resist Updat"},{"issue":"8","key":"5_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1109\/TNB.2016.2621730","volume":"15","author":"A Babu","year":"2016","unstructured":"Babu A, Muralidharan R, Amreddy N, Mehta M, Munshi A, Ramesh R (2016) Nanoparticles for siRNA-based gene silencing in tumor therapy. IEEE Trans Nanobioscience 15(8):849\u2013863. https:\/\/doi.org\/10.1109\/TNB.2016.2621730. PMID: 28092499; PMCID: PMC6198667","journal-title":"IEEE Trans Nanobioscience"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"1450014","DOI":"10.3389\/fimmu.2024.1450014","volume":"15","author":"Y Bai","year":"2024","unstructured":"Bai Y, Gao J, Yan Y, Zhao X (2024) The significance of long chain non-coding RNA signature genes in the diagnosis and management of sepsis patients, and the development of a prediction model. Front Immunol 15:1450014","journal-title":"Front Immunol"},{"issue":"2","key":"5_CR12","first-page":"203","volume":"11","author":"SL Beaucage","year":"2008","unstructured":"Beaucage SL (2008) Solid-phase synthesis of siRNA oligonucleotides. Curr Opin Drug Discov Devel 11(2):203\u2013216","journal-title":"Curr Opin Drug Discov Devel"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF (2019) Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med 70:307\u2013321","journal-title":"Annu Rev Med"},{"issue":"6818","key":"5_CR14","doi-asserted-by":"publisher","first-page":"363\u20136","DOI":"10.1038\/35053110","volume":"409","author":"E Bernstein","year":"2001","unstructured":"Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818):363\u20136","journal-title":"Nature"},{"issue":"9","key":"5_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/15476286.2019.1621624","volume":"16","author":"S Bhattacharjee","year":"2019","unstructured":"Bhattacharjee S, Roche B, Martienssen RA (2019) RNA-induced initiation of transcriptional silencing (RITS) complex structure and function. RNA Biol 16(9):1133\u20131146. https:\/\/doi.org\/10.1080\/15476286.2019.1621624. Epub 2019 Jun 18. PMID: 31213126; PMCID: PMC6693537","journal-title":"RNA Biol"},{"issue":"7315","key":"5_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596\u2013599","journal-title":"Nature"},{"key":"5_CR17","first-page":"9","volume":"6","author":"RS Bora","year":"2012","unstructured":"Bora RS, Gupta D, Mukkur TK, Saini KS (2012) RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Rep 6:9\u201315","journal-title":"Mol Med Rep"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2009.12.002","volume":"36","author":"A Bosch","year":"2010","unstructured":"Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206\u2013215","journal-title":"Cancer Treat Rev"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1021\/bm800664c","volume":"9","author":"C Bouclier","year":"2008","unstructured":"Bouclier C, Moine L, Hillaireau H, Marsaud V, Connault E, Opolon P, Couvreur P, Fattal E, Renoir JM (2008) Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha. Biomacromolecules 9:2881\u20132890","journal-title":"Biomacromolecules"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-62703-119-6_5","volume":"942","author":"JB Bramsen","year":"2013","unstructured":"Bramsen JB, Kjems J (2013) Engineering small interfering RNAs by strategic chemical modification. Methods Mol Biol 942:87\u2013109","journal-title":"Methods Mol Biol"},{"issue":"9","key":"5_CR21","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21(9):3233","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nchembio839","volume":"2","author":"D Bumcrot","year":"2006","unstructured":"Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711\u2013719","journal-title":"Nat Chem Biol"},{"issue":"1","key":"5_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","volume":"19","author":"JC Burnett","year":"2012","unstructured":"Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19(1):60\u201371. https:\/\/doi.org\/10.1016\/j.chembiol.2011.12.008. PMID: 22284355; PMCID: PMC3269031","journal-title":"Chem Biol"},{"issue":"8","key":"5_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/1521-1878(200008)22:8<697::AID-BIES3>3.0.CO;2-1","volume":"22","author":"G Carpenter","year":"2000","unstructured":"Carpenter G (2000) The EGF receptor: a nexus for trafficking and signaling. BioEssays 22(8):697\u2013707","journal-title":"BioEssays"},{"issue":"4","key":"5_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","volume":"136","author":"RW Carthew","year":"2009","unstructured":"Carthew RW, Sontheimer EJ (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136(4):642\u2013655","journal-title":"Cell"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","volume":"9","author":"S Casacuberta-Serra","year":"2024","unstructured":"Casacuberta-Serra S, Gonz\u00e1lez-Larreategui \u00cd, Capit\u00e1n-Leo D et al (2024) MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Sig Transduct Target Ther 9:205","journal-title":"Sig Transduct Target Ther"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrg3355","volume":"14","author":"SE Castel","year":"2013","unstructured":"Castel SE, Martienssen RA (2013) RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet 14:100\u2013112","journal-title":"Nat Rev Genet"},{"issue":"1","key":"5_CR28","first-page":"23","volume":"14","author":"WH Chappell","year":"2014","unstructured":"Chappell WH, Lasky M (2014) Targeting MYC in cancer therapy. Nat Rev Cancer 14(1):23\u201335","journal-title":"Nat Rev Cancer"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/smll.200900621","volume":"5","author":"AM Chen","year":"2009","unstructured":"Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, He H (2009) Co-delivery of doxorubicin and Bcl-2 SiRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5:2673","journal-title":"Small"},{"issue":"12","key":"5_CR30","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1172\/JCI33483","volume":"117","author":"DR Corey","year":"2007","unstructured":"Corey DR (2007) Chemical modification: the key to clinical application of RNA interference? J Clin Invest 117(12):3615\u20133622","journal-title":"J Clin Invest"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.nantod.2012.06.013","volume":"7","author":"M Creixell","year":"2012","unstructured":"Creixell M, Peppas NA (2012) Co-delivery of SiRNA and therapeutic agents using Nanocarriers to overcome cancer resistance. Nano Today 7:367","journal-title":"Nano Today"},{"issue":"1","key":"5_CR32","doi-asserted-by":"publisher","first-page":"e10374","DOI":"10.1002\/btm2.10374","volume":"8","author":"A Curreri","year":"2022","unstructured":"Curreri A, Sankholkar D, Mitragotri S, Zhao Z (2022) RNA therapeutics in the clinic. Bioeng Transl Med 8(1):e10374","journal-title":"Bioeng Transl Med"},{"issue":"2","key":"5_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","volume":"13","author":"H Dana","year":"2017","unstructured":"Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, Mehmandoost N, Moazzen F, Mazraeh A, Marmari V, Ebrahimi M, Rashno MM, Abadi SJ, Gharagouzlo E (2017) Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci 13(2):48\u201357. PMID: 28824341; PMCID: PMC5542916","journal-title":"Int J Biomed Sci"},{"issue":"5","key":"5_CR34","first-page":"881","volume":"19","author":"OJP De La","year":"2011","unstructured":"De La OJP, McDonald PC (2011) Targeting KRAS in cancer therapy: from laboratory to clinical trials. Mol Ther 19(5):881\u2013888","journal-title":"Mol Ther"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3390\/molecules24040809","volume":"24","author":"BG de la Torre","year":"2019","unstructured":"de la Torre BG, Albericio F (2019) The Pharmaceutical Industry in 2018. An analysis of FDA drug approvals from the perspective of molecules. Molecules 24:809","journal-title":"Molecules"},{"issue":"13","key":"5_CR36","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1093\/nar\/gkq181","volume":"38","author":"GF Deleavey","year":"2010","unstructured":"Deleavey GF, Watts JK, Alain T, Robert F, Kalota A, Aishwarya V, Pelletier J, Gewirtz AM, Sonenberg N, Damha MJ (2010) Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res 38(13):4547\u20134557. https:\/\/doi.org\/10.1093\/nar\/gkq181. Epub 2010 Apr 22. PMID: 20413581; PMCID: PMC2910058","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"5_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","volume":"30","author":"F Dietlein","year":"2014","unstructured":"Dietlein F, Thelen L, Reinhardt HC (2014) Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 30(8):326\u2013339","journal-title":"Trends Genet"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG (2019) Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 144:133\u2013147","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"5_CR39","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/ijms26083456","volume":"26","author":"O Ebenezer","year":"2025","unstructured":"Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, Wong GK (2025) Recent update on siRNA therapeutics. Int J Mol Sci 26(8):3456. https:\/\/doi.org\/10.3390\/ijms26083456. PMID: 40331977; PMCID: PMC12026779","journal-title":"Int J Mol Sci"},{"issue":"7778","key":"5_CR40","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/d41586-019-03069-3","volume":"574","author":"M Eisenstein","year":"2019","unstructured":"Eisenstein M (2019) Pharma\u2019s roller-coaster relationship with RNA therapies. Nature 574(7778):S4","journal-title":"Nature"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium","year":"2012","unstructured":"ENCODE Project Consortium (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57\u201374","journal-title":"Nature"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.addr.2009.04.005","volume":"61","author":"T Endoh","year":"2009","unstructured":"Endoh T, Ohtsuki T (2009) Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 61:704\u2013709","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"5_CR43","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov Y, Anderson EM, Birmingham A et al (2006) Off-target effects by siRNA can induce toxic phenotype. RNA 12(7):1188\u20131196","journal-title":"RNA"},{"key":"5_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.710738","volume":"8","author":"R Feng","year":"2021","unstructured":"Feng R, Patil S, Zhao X, Miao Z, Qian A (2021) RNA therapeutics - research and clinical advancements. Front Mol Biosci 8:710738. https:\/\/doi.org\/10.3389\/fmolb.2021.710738. PMID: 34631795; PMCID: PMC8492966","journal-title":"Front Mol Biosci"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811","journal-title":"Nature"},{"issue":"1","key":"5_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376(1):41\u201351","journal-title":"N Engl J Med"},{"issue":"5","key":"5_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A (2022) Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs 36(5):549\u2013571. https:\/\/doi.org\/10.1007\/s40259-022-00549-3. Epub 2022 Aug 23. PMID: 35997897; PMCID: PMC9396607","journal-title":"BioDrugs"},{"issue":"2","key":"5_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/nsr\/nwu008","volume":"1","author":"X-D Fu","year":"2014","unstructured":"Fu X-D (2014) Non-coding RNA: a new frontier in regulatory biology. Natl Sci Rev 1(2):190\u2013204","journal-title":"Natl Sci Rev"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1038\/srep03325","volume":"3","author":"Y Fujita","year":"2013","unstructured":"Fujita Y, Takeshita F, Mizutani T, Ohgi T, Kuwano K, Ochiya T (2013) A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci Rep 3:3325","journal-title":"Sci Rep"},{"issue":"7","key":"5_CR50","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2174\/138955710791384036","volume":"10","author":"M Gaglione","year":"2010","unstructured":"Gaglione M, Messere A (2010) Recent progress in chemically modified siRNAs. Mini Rev Med Chem 10(7):578\u2013595","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"5_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massague J (2021) Targeting metastatic cancer. Nat Med 27(1):34\u201344","journal-title":"Nat Med"},{"issue":"3","key":"5_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1745-7254.2005.00053.x","volume":"26","author":"X Gao Lf","year":"2005","unstructured":"Gao Lf X, Dq WL, Xy Z, Yt S, Xj Z (2005) Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 26(3):377\u2013383","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"5_CR53","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nbt0918-777","volume":"36","author":"K Garber","year":"2018","unstructured":"Garber K (2018) Alnylam launches era of RNAi drugs. Nat Biotechnol 36(9):777\u2013778","journal-title":"Nat Biotechnol"},{"issue":"27","key":"5_CR54","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","volume":"6","author":"T Golan","year":"2015","unstructured":"Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E (2015) RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 6(27):24560\u201324570. https:\/\/doi.org\/10.18632\/oncotarget.4183. PMID: 26009994; PMCID: PMC4695206","journal-title":"Oncotarget"},{"key":"5_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.985670","volume":"13","author":"R Goyal","year":"2022","unstructured":"Goyal R, Chopra H, Singh I, Dua K, Gautam RK (2022) Insights on prospects of nano-siRNA based approaches in treatment of cancer. Front Pharmacol 13:985670. https:\/\/doi.org\/10.3389\/fphar.2022.985670. PMID: 36091772; PMCID: PMC9452808","journal-title":"Front Pharmacol"},{"issue":"4","key":"5_CR56","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/bit.21798","volume":"100","author":"JA Gredell","year":"2008","unstructured":"Gredell JA, Berger AK, Walton SP (2008) Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study. Biotechnol Bioeng 100(4):744\u2013755. https:\/\/doi.org\/10.1002\/bit.21798. PMID: 18306428; PMCID: PMC2658823","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"5_CR57","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2021.5964","volume":"8","author":"DR Grimes","year":"2022","unstructured":"Grimes DR (2022) Radiofrequency radiation and cancer: a review. JAMA Oncol 8(3):456\u2013461","journal-title":"JAMA Oncol"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/cancers12051238","volume":"12","author":"C Gul\u00eca","year":"2020","unstructured":"Gul\u00eca C, Signore F, Gaffi M, Gigli S, Votino R, Nucciotti R, Bertacca L, Zaami S, Baffa A, Santini E et al (2020) Y RNA: An overview of their role as potential biomarkers and molecular targets in human cancers. Cancer 12:1238","journal-title":"Cancer"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molmed.2013.02.002","volume":"19","author":"J Guo","year":"2013","unstructured":"Guo J, Evans JC, O\u2019Driscoll CM (2013) Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? Trends Mol Med 19:250\u2013261","journal-title":"Trends Mol Med"},{"key":"5_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15:509\u2013524","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00018-020-03675-9","volume":"78","author":"JC Hahne","year":"2021","unstructured":"Hahne JC, Lampis A, Valeri N (2021) Vault RNAs: hidden gems in RNA and protein regulation. Cell Mol Life Sci 78:1487\u20131499","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31\u201346","journal-title":"Cancer Discov"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"key":"5_CR64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3389\/fgene.2019.00478","volume":"10","author":"J Hanna","year":"2019","unstructured":"Hanna J, Hossain GS, Kocerha J (2019) The potential for microRNA therapeutics and clinical research. Front Genet 10:478","journal-title":"Front Genet"},{"issue":"6894","key":"5_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/418244a","volume":"418","author":"GJ Hannon","year":"2002","unstructured":"Hannon GJ (2002) RNA interference. Nature 418(6894):244\u2013251","journal-title":"Nature"},{"issue":"7","key":"5_CR66","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","volume":"13","author":"D Hattab","year":"2021","unstructured":"Hattab D, Gazzali AM, Bakhtiar A (2021) Clinical advances of siRNA-based Nanotherapeutics for cancer treatment. Pharmaceutics. 13(7):1009. https:\/\/doi.org\/10.3390\/pharmaceutics13071009. PMID: 34371702; PMCID: PMC8309123","journal-title":"Pharmaceutics."},{"issue":"5","key":"5_CR67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","volume":"38","author":"D Ho","year":"2020","unstructured":"Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A (2020) Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol 38(5):497\u2013518. https:\/\/doi.org\/10.1016\/j.tibtech.2019.12.021. Epub 2020 Jan 21. PMID: 31980301; PMCID: PMC7924935","journal-title":"Trends Biotechnol"},{"key":"5_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/bcr945","volume":"6","author":"A Howell","year":"2004","unstructured":"Howell A, Dowsett M (2004) Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 6:269\u2013274","journal-title":"Breast Cancer Res"},{"issue":"15","key":"5_CR69","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1093\/nar\/gkh790","volume":"32","author":"X Hu","year":"2004","unstructured":"Hu X, Hipolito S, Lynn R, Abraham V, Ramos S, Wong-Staal F (2004) Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res 32(15):4609\u20134617. https:\/\/doi.org\/10.1093\/nar\/gkh790. PMID: 15333693; PMCID: PMC516062","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ (2020) Therapeutic siRNA: state of the art. Signal Transduct Target Ther 5(1):101","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"5_CR71","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","volume":"29","author":"A Idris","year":"2021","unstructured":"Idris A, Davis A, Supramaniam A et al (2021) A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther 29(7):2219\u20132226","journal-title":"Mol Ther"},{"key":"5_CR72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-biochem-060614-034258","volume":"84","author":"YW Iwasaki","year":"2015","unstructured":"Iwasaki YW, Siomi MC, Siomi H (2015) PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem 84:405\u2013433","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"5_CR73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nbt831","volume":"21","author":"AL Jackson","year":"2003","unstructured":"Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M et al (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21(6):635\u2013637","journal-title":"Nat Biotechnol"},{"issue":"23","key":"5_CR74","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL (2015) Precision medicine\u2014personalized, problematic, and promising. N Engl J Med 372(23):2229\u20132234","journal-title":"N Engl J Med"},{"issue":"1","key":"5_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.7150\/thno.67300","volume":"12","author":"B Ji","year":"2022","unstructured":"Ji B, Wei M, Yang B (2022) Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. Theranostics 12(1):434\u2013458","journal-title":"Theranostics"},{"issue":"4","key":"5_CR76","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1517\/17425247.2016.1134486","volume":"13","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Huo S, Hardie J, Liang XJ, Rotello VM (2016) Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv 13(4):547\u2013559. https:\/\/doi.org\/10.1517\/17425247.2016.1134486. Epub 2016 Jan 14. PMID: 26735861; PMCID: PMC4914043","journal-title":"Expert Opin Drug Deliv"},{"key":"5_CR77","doi-asserted-by":"publisher","first-page":"E2572","DOI":"10.1073\/pnas.1304318110","volume":"110","author":"Y Jin","year":"2013","unstructured":"Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Maelandsmo GM, Kong H, Zhang T, Jeronimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F (2013) Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci USA 110:E2572\u2013E2581","journal-title":"Proc Natl Acad Sci USA"},{"key":"5_CR78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2007.179","volume":"19","author":"A Judge","year":"2008","unstructured":"Judge A, Maclachlan I (2008) Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19:111\u2013124","journal-title":"Hum Gene Ther"},{"key":"5_CR79","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457\u2013462","journal-title":"Nat Biotechnol"},{"issue":"12","key":"5_CR80","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1093\/nar\/gkn342","volume":"36","author":"R Juliano","year":"2008","unstructured":"Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36(12):4158\u20134171","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"5_CR81","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689\u2013698","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5_CR82","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/cvr\/cvr097","volume":"90","author":"MU Kaikkonen","year":"2011","unstructured":"Kaikkonen MU, Lam MT, Glass CK (2011) Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 90(3):430\u2013440. https:\/\/doi.org\/10.1093\/cvr\/cvr097. Epub 2011 May 9. PMID: 21558279; PMCID: PMC3096308","journal-title":"Cardiovasc Res"},{"issue":"11","key":"5_CR83","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967\u2013977","journal-title":"Nat Mater"},{"issue":"1","key":"5_CR84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/1541-7786.MCR-16-0341","volume":"16","author":"T Kato","year":"2018","unstructured":"Kato T, Lee D, Huang H, Cruz W, Ujiie H, Fujino K, Wada H, Patel P, Hu HP, Hirohashi K, Nakajima T, Sato M, Kaji M, Kaga K, Matsui Y, Chen J, Zheng G, Yasufuku K (2018) Personalized siRNA-nanoparticle systemic therapy using metastatic lymph node specimens obtained with EBUS-TBNA in lung cancer. Mol Cancer Res 16(1):47\u201357. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0341. Epub 2017 Oct 9. PMID: 28993508","journal-title":"Mol Cancer Res"},{"issue":"5","key":"5_CR85","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13(5):273\u2013290","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"5_CR86","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbagrm.2011.05.001","volume":"1819","author":"B Khraiwesh","year":"2012","unstructured":"Khraiwesh B, Zhu JK, Zhu J (2012) Role of miRNAs and siRNAs in biotic and abiotic stress responses of plants. Biochim Biophys Acta 1819(2):137\u2013148. https:\/\/doi.org\/10.1016\/j.bbagrm.2011.05.001. Epub 2011 May 13. PMID: 21605713; PMCID: PMC3175014","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"5_CR87","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35(3):238\u2013248","journal-title":"Nat Biotechnol"},{"issue":"9","key":"5_CR88","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrg.2016.105","volume":"17","author":"L Koch","year":"2016","unstructured":"Koch L (2016) Genetic screen: a network to guide precision cancer therapy. Nat Rev Genet 17(9):504\u2013505","journal-title":"Nat Rev Genet"},{"issue":"3","key":"5_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/diseases6030063","volume":"6","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Munoz Estrella A, Sourlas A et al (2018) Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases 6(3):63","journal-title":"Diseases"},{"key":"5_CR90","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, Rudra A, Miao L, Anderson DG (2019) Delivering the messenger: advances in Technologies for therapeutic mRNA delivery. Mol Ther 27:710\u2013728","journal-title":"Mol Ther"},{"key":"5_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100103","volume":"3","author":"K Kumar","year":"2022","unstructured":"Kumar K, Rani V, Mishra M, Chawla R (2022) New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Curr Res Pharmacol Drug Discov 3:100103. https:\/\/doi.org\/10.1016\/j.crphar.2022.100103. PMID: 35586474; PMCID: PMC9108887","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"5_CR92","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.2012.396","volume":"107","author":"J Kurashige","year":"2012","unstructured":"Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K, Baba H (2012) RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer 107:1233\u20131238","journal-title":"Br J Cancer"},{"key":"5_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-1-4939-2291-8_25","volume-title":"RNA bioinformatics Methods in molecular biology","author":"A Lagan\u00e0","year":"2015","unstructured":"Lagan\u00e0 A, Veneziano D, Russo F, Pulvirenti A, Giugno R, Croce CM, Ferro A (2015) Computational design of artificial RNA molecules for gene regulation. In: RNA bioinformatics Methods in molecular biology, vol 1269. Springer, New York, pp 393\u2013412"},{"issue":"1","key":"5_CR94","doi-asserted-by":"publisher","first-page":"69\u201381","DOI":"10.1016\/S0092-8674(04)00261-2","volume":"117","author":"YS Lee","year":"2004","unstructured":"Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ, Carthew RW (2004) Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA\/miRNA silencing pathways. Cell 117(1):69\u201381","journal-title":"Cell"},{"key":"5_CR95","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.05.010","volume":"104","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Kim MJ, Kwon IC, Roberts TM (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2\u201315. https:\/\/doi.org\/10.1016\/j.addr.2016.05.010. Epub 2016 May 31. PMID: 27259398; PMCID: PMC4958528","journal-title":"Adv Drug Deliv Rev"},{"key":"5_CR96","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2020.04.023","volume":"485","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) Non-coding RNA in bladder cancer. Cancer Lett 485:38\u201344","journal-title":"Cancer Lett"},{"key":"5_CR97","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41392-021-00779-x","volume":"6","author":"C Li","year":"2021","unstructured":"Li C, Ni Y-Q, Xu H, Xiang Q-Y, Zhao Y, Zhan J-K, He J-Y, Li S, Liu Y-S (2021a) Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther 6:383","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"5_CR98","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1631\/jzus.B2100009","volume":"22","author":"C Li","year":"2021","unstructured":"Li C, Brant E, Budak H, Zhang B (2021b) CRISPR\/Cas: a Nobel prize award-winning precise genome editing technology for gene therapy and crop improvement. J Zhejiang Univ Sci B 22(4):253\u2013284","journal-title":"J Zhejiang Univ Sci B"},{"key":"5_CR99","doi-asserted-by":"publisher","first-page":"124","DOI":"10.15212\/bioi-2021-0032","volume":"3","author":"X Li","year":"2022","unstructured":"Li X, Loh TJ, Lim JJ, Er SP, Liao Y (2022) Glycan-RNA: a new class of non-coding RNA. BIO Integr 3:124\u2013131","journal-title":"BIO Integr"},{"key":"5_CR100","first-page":"203","volume":"12","author":"SA Lim","year":"2022","unstructured":"Lim SA, Cox A, Tung M, Chung EJ (2022) Clinical progress of nanomedicine-based RNA therapies. Bioact Mater 12:203\u2013213","journal-title":"Bioact Mater"},{"issue":"13","key":"5_CR101","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.7150\/thno.87316","volume":"13","author":"L Lin","year":"2023","unstructured":"Lin L, Su K, Cheng Q, Liu S (2023) Targeting materials and strategies for RNA delivery. Theranostics 13(13):4667\u20134693. https:\/\/doi.org\/10.7150\/thno.87316. PMID: 37649616; PMCID: PMC10465230","journal-title":"Theranostics"},{"key":"5_CR102","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2014.07.001","volume":"192","author":"Y Liu","year":"2014","unstructured":"Liu Y, Zhu YH, Mao CQ, Dou S, Shen S, Tan ZB, Wang J (2014) Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J Control Release 192:114\u2013121","journal-title":"J Control Release"},{"issue":"1","key":"5_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10142-022-00947-4","volume":"23","author":"T Loganathan","year":"2023","unstructured":"Loganathan T, Doss CGP (2023) Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. Funct Integr Genomics 23(1):33","journal-title":"Funct Integr Genomics"},{"issue":"12","key":"5_CR104","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X et al (2019) Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci 15(12):2548\u20132560","journal-title":"Int J Biol Sci"},{"key":"5_CR105","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.2147\/IJN.S200253","volume":"14","author":"G Mahmoodi Chalbatani","year":"2019","unstructured":"Mahmoodi Chalbatani G, Dana H, Gharagouzloo E, Grijalvo S, Eritja R, Logsdon CD, Memari F, Miri SR, Rad MR, Marmari V (2019) Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int J Nanomedicine 14:3111\u20133128. https:\/\/doi.org\/10.2147\/IJN.S200253. PMID: 31118626; PMCID: PMC6504672","journal-title":"Int J Nanomedicine"},{"key":"5_CR106","first-page":"313","volume":"57","author":"M Manoharan","year":"2017","unstructured":"Manoharan M (2017) Therapeutic applications of siRNA-based drugs. Annu Rev Pharmacol Toxicol 57:313\u2013331","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"5_CR107","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/nbt1161","volume":"23","author":"JT Marques","year":"2005","unstructured":"Marques JT, Williams BRG (2005) Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23(11):1399\u20131405","journal-title":"Nat Biotechnol"},{"issue":"4","key":"5_CR108","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28(4):658\u2013665","journal-title":"Nat Med"},{"key":"5_CR109","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1126\/science.1234139","volume":"339","author":"HL McLeod","year":"2013","unstructured":"McLeod HL (2013) Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339:1563\u20131566","journal-title":"Science"},{"key":"5_CR110","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijpharm.2012.04.028","volume":"431","author":"A Minai-Tehrani","year":"2012","unstructured":"Minai-Tehrani A, Jiang HL, Kim YK, Chung YS, Yu KN, Kim JE, Shin JY, Hong SH, Lee JH, Kim HJ, Chang SH, Park S, Kang BN, Cho CS, Cho MH (2012) Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly (amino ester). Int J Pharm 431:197\u2013203","journal-title":"Int J Pharm"},{"issue":"4","key":"5_CR111","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1517\/17425247.2011.561313","volume":"8","author":"X Ming","year":"2011","unstructured":"Ming X (2011) Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin Drug Deliv 8(4):435\u2013449","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"5_CR112","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.3390\/cells10123348","volume":"10","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP (2021) Pre-clinical and clinical applications of small interfering RNAs (siRNA) and co-delivery systems for pancreatic cancer therapy. Cells 10(12):3348. https:\/\/doi.org\/10.3390\/cells10123348. PMID: 34943856; PMCID: PMC8699513","journal-title":"Cells"},{"issue":"1","key":"5_CR113","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood.V81.1.151.151","volume":"81","author":"T Miyashita","year":"1993","unstructured":"Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81(1):151\u2013157. PMID: 8417786","journal-title":"Blood"},{"key":"5_CR114","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584\u2013594","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"5_CR115","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1534\/g3.117.044024","volume":"7","author":"I Monga","year":"2017","unstructured":"Monga I, Qureshi A, Thakur N, Gupta AK, Kumar M (2017) aspsirna: a resource of asp-sirnas having therapeutic potential for human genetic disorders and algorithm for prediction of their inhibitory efficacy. G3: Genes Genomes Genet 7(9):2931\u20132943","journal-title":"G3: Genes Genomes Genet"},{"issue":"1","key":"5_CR116","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jb\/mvg019","volume":"133","author":"H Mukai","year":"2003","unstructured":"Mukai H (2003) The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J Biochem 133(1):17\u201327","journal-title":"J Biochem"},{"key":"5_CR117","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-800148-6.00009-2","volume":"88","author":"P Neuberg","year":"2014","unstructured":"Neuberg P, Kichler A (2014) Recent developments in nucleic acid delivery with polyethylenimines. Adv Genet 88:263\u2013288","journal-title":"Adv Genet"},{"key":"5_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202107550","volume":"18","author":"W Ngamcherdtrakul","year":"2022","unstructured":"Ngamcherdtrakul W, Bejan DS, Cruz-Mu\u00f1oz W, Reda M, Zaidan HY, Siriwon N, Marshall S, Wang R, Nelson MA, Rehwaldt JPC et al (2022) Targeted nanoparticle for co-delivery of HER2 SiRNA and a Taxane to Mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis. Small 18:2107550","journal-title":"Small"},{"issue":"2","key":"5_CR119","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4161\/cbt.5.2.2317","volume":"5","author":"F Niola","year":"2006","unstructured":"Niola F, Evangelisti C, Campagnola L, Massalini S, Bu\u00e8 MC, Mangiola A, Masotti A, Maira G, Farace MG, Ciafr\u00e8 SA (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 5(2):174\u2013179","journal-title":"Cancer Biol Ther"},{"key":"5_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H (2021) Anticancer drug resistance: an update and perspective. Drug Resist Updat 59:100796","journal-title":"Drug Resist Updat"},{"issue":"10","key":"5_CR121","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","volume":"61","author":"YK Oh","year":"2009","unstructured":"Oh YK, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61(10):850\u2013862","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"5_CR122","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ijpharm.2006.11.050","volume":"331","author":"S Oliveira","year":"2007","unstructured":"Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM (2007) Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm 331(2):211\u2013214","journal-title":"Int J Pharm"},{"issue":"1","key":"5_CR123","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2796.2009.02191.x","volume":"267","author":"B Ozpolat","year":"2010","unstructured":"Ozpolat B, Sood AK, Lopez-Berestein G (2010) Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267(1):44\u201353","journal-title":"J Intern Med"},{"key":"5_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2022.100063","volume":"7","author":"A Paul","year":"2022","unstructured":"Paul A, Muralidharan A, Biswas A, Kamath BV, Joseph A, Alex AT (2022) siRNA therapeutics and its challenges: recent advances in effective delivery for cancer therapy. OpenNano 7:100063","journal-title":"OpenNano"},{"issue":"1","key":"5_CR125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1261\/rna5160904","volume":"10","author":"SP Persengiev","year":"2004","unstructured":"Persengiev SP, Zhu X, Green MR (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10(1):12\u201318","journal-title":"RNA"},{"issue":"27","key":"5_CR126","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.R900012200","volume":"284","author":"AJ Pratt","year":"2009","unstructured":"Pratt AJ, MacRae IJ (2009) The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 284(27):17897\u201317901. https:\/\/doi.org\/10.1074\/jbc.R900012200. Epub 2009 Apr 1. PMID: 19342379; PMCID: PMC2709356","journal-title":"J Biol Chem"},{"issue":"3","key":"5_CR127","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jconrel.2012.01.045","volume":"159","author":"MA Rahman","year":"2012","unstructured":"Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM (2012) Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release 159(3):384\u2013392. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.045. Epub 2012 Feb 8. PMID: 22342644; PMCID: PMC3348392","journal-title":"J Control Release"},{"issue":"4","key":"5_CR128","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1471-4892(02)00178-9","volume":"2","author":"A Reddy","year":"2002","unstructured":"Reddy A, Kaelin WG Jr (2002) Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol 2(4):366\u2013373","journal-title":"Curr Opin Pharmacol"},{"key":"5_CR129","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/oli.2009.0180","volume":"19","author":"M Robbins","year":"2009","unstructured":"Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19:89\u2013102","journal-title":"Oligonucleotides"},{"issue":"2","key":"5_CR130","doi-asserted-by":"publisher","first-page":"238","DOI":"10.20524\/aog.2016.0024","volume":"29","author":"S Russo","year":"2016","unstructured":"Russo S, Saif MW (2016) Gastrointestinal cancers symposium: update on pancreatic cancer. Ann Gastroenterol 29(2):238\u2013240","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"5_CR131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.gt.3302356","volume":"12","author":"RCC Ryther","year":"2005","unstructured":"Ryther RCC, Flynt AS, Phillips J, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12(1):5\u201311","journal-title":"Gene Ther"},{"issue":"10","key":"5_CR132","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/ph13100294","volume":"13","author":"MI Sajid","year":"2020","unstructured":"Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK (2020a) Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals 13(10):294","journal-title":"Pharmaceuticals"},{"issue":"10","key":"5_CR133","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/ph13100294","volume":"13","author":"MI Sajid","year":"2020","unstructured":"Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK (2020b) Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals (Basel) 13(10):294. https:\/\/doi.org\/10.3390\/ph13100294. PMID: 33036435; PMCID: PMC7600125","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"5_CR134","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/nat.2012.0414","volume":"23","author":"Y S\u00e1nchez","year":"2013","unstructured":"S\u00e1nchez Y, Huarte M (2013) Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther 23(1):15\u201320. https:\/\/doi.org\/10.1089\/nat.2012.0414. PMID: 23391415; PMCID: PMC3569944","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"5_CR135","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2010.07.045","volume":"399","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Nakashiro K, Tanaka H et al (2010) Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun 399(1):79\u201383","journal-title":"Biochem Biophys Res Commun"},{"key":"5_CR136","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","volume":"63","author":"PE Saw","year":"2020","unstructured":"Saw PE, Song EW (2020) siRNA therapeutics: a clinical reality. Sci China Life Sci 63:485\u2013500","journal-title":"Sci China Life Sci"},{"issue":"5","key":"5_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101555","volume":"5","author":"PE Saw","year":"2024","unstructured":"Saw PE, Song E (2024) Advancements in clinical RNA therapeutics: present developments and prospective outlooks. Cell Rep Med 5(5):101555","journal-title":"Cell Rep Med"},{"key":"5_CR138","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.3390\/cancers12113130","volume":"12","author":"B Schultheis","year":"2020","unstructured":"Schultheis B, Strumberg D, Kuhlmann J, Wolf M, Link K, Seufferlein T, Kaufmann J, Feist M, Gebhardt F, Khan M et al (2020) Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ib\/IIa study. Cancers 12:3130","journal-title":"Cancers"},{"issue":"6","key":"5_CR139","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP (2019a) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18(6):421\u2013446","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR140","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP (2019b) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421\u2013446","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR141","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.semcancer.2017.11.004","volume":"56","author":"S Shakil","year":"2019","unstructured":"Shakil S, Baig MH, Tabrez S et al (2019) Molecular and enzoinformatics perspectives of targeting polo-like kinase 1 in cancer therapy. Semin Cancer Biol 56:47\u201355","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"5_CR142","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205\u2013214","journal-title":"Cell"},{"issue":"10","key":"5_CR143","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1021\/mp500426r","volume":"11","author":"RS Shukla","year":"2014","unstructured":"Shukla RS, Qin B, Cheng K (2014) Peptides used in the delivery of small noncoding RNA. Mol Pharm 11(10):3395\u20133408","journal-title":"Mol Pharm"},{"issue":"2","key":"5_CR144","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","volume":"46","author":"A Singh","year":"2018","unstructured":"Singh A, Trivedi P, Jain NK (2018) Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol 46(2):274\u2013283","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"5","key":"5_CR145","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","volume":"179","author":"FJ Slack","year":"2019","unstructured":"Slack FJ, Chinnaiyan AM (2019) The role of non-coding RNAs in oncology. Cell 179(5):1033\u20131055","journal-title":"Cell"},{"issue":"1","key":"5_CR146","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","volume":"59","author":"CE Smith","year":"2019","unstructured":"Smith CE, Zain R (2019) Therapeutic oligonucleotides: state of the art. Annu Rev Pharmacol Toxicol 59(1):605\u2013630","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5_CR147","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/onco5010002","volume":"5","author":"C Sousa","year":"2025","unstructured":"Sousa C, Videira M (2025) Dual approaches in oncology: the promise of siRNA and chemotherapy combinations in cancer therapies. Onco 5:2","journal-title":"Onco"},{"key":"5_CR148","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trsl.2019.07.006","volume":"214","author":"MA Subhan","year":"2019","unstructured":"Subhan MA, Torchilin VP (2019) Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res 214:62\u201391","journal-title":"Transl Res"},{"key":"5_CR149","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1126\/science.1230184","volume":"339","author":"ML Suva","year":"2013","unstructured":"Suva ML, Riggi N, Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339:1567\u20131570","journal-title":"Science"},{"key":"5_CR150","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406","journal-title":"Cancer Discov"},{"issue":"1","key":"5_CR151","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41598-020-58995-4","volume":"10","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Asaoka M, Yan L, Rashid OM, Oshi M, Ishikawa T, Nagahashi M, Takabe K (2020) Biologically aggressive phenotype and anti-cancer immunity counterbalance in breast cancer with high mutation rate. Sci Rep 10(1):1852","journal-title":"Sci Rep"},{"issue":"3","key":"5_CR152","doi-asserted-by":"publisher","first-page":"142\u201351","DOI":"10.1002\/emmm.200900023","volume":"1","author":"K Tiemann","year":"2009","unstructured":"Tiemann K, Rossi JJ (2009) RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1(3):142\u201351","journal-title":"EMBO Mol Med"},{"issue":"5","key":"5_CR153","doi-asserted-by":"publisher","first-page":"517\u201329","DOI":"10.1101\/gad.1284105","volume":"19","author":"Y Tomari","year":"2005","unstructured":"Tomari Y, Zamore PD (2005) Perspective: machines for RNAi. Genes Dev 19(5):517\u201329","journal-title":"Genes Dev"},{"issue":"6766","key":"5_CR154","first-page":"838","volume":"403","author":"T Tuschl","year":"2001","unstructured":"Tuschl T et al (2001) Targeted gene silencing using duplex RNA in mammalian cells. Nature 403(6766):838\u2013842","journal-title":"Nature"},{"issue":"10","key":"5_CR155","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1021\/acs.molpharmaceut.0c00618","volume":"17","author":"S Uchida","year":"2020","unstructured":"Uchida S, Perche F, Pichon C, Cabral H (2020) Nanomedicine-based approaches for mRNA delivery. Mol Pharm 17(10):3654\u20133684","journal-title":"Mol Pharm"},{"issue":"2","key":"5_CR156","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275\u2013292","journal-title":"Cell"},{"issue":"5","key":"5_CR157","first-page":"799","volume":"9","author":"VV Vlassov","year":"2012","unstructured":"Vlassov VV, An D (2012) Exosome-mediated RNA delivery. RNA Biol 9(5):799\u2013808","journal-title":"RNA Biol"},{"key":"5_CR158","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/CCO.0000000000000004","volume":"25","author":"W Walther","year":"2013","unstructured":"Walther W, Schlag PM (2013) Current status of gene therapy for cancer. Curr Opin Oncol 25:659\u2013664","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"5_CR160","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","volume":"43","author":"KC Wang","year":"2011","unstructured":"Wang KC, Chang HY (2011) Molecular mechanisms of long noncoding RNAs. Mol Cell 43(6):904\u2013914","journal-title":"Mol Cell"},{"key":"5_CR161","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/jcb.22451","volume":"109","author":"Z Wang","year":"2010","unstructured":"Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH (2010a) Down-regulation of notch-1 and jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 109:726\u2013736","journal-title":"J Cell Biochem"},{"key":"5_CR162","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","volume":"12","author":"J Wang","year":"2010","unstructured":"Wang J, Lu Z, Wientjes MG, Au JLS (2010b) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12:492\u2013503","journal-title":"AAPS J"},{"key":"5_CR163","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.045","volume":"387","author":"T Wang","year":"2017","unstructured":"Wang T, Shigdar S, Shamaileh HA, Gantier MP, Yin W, Xiang D, Wang L, Zhou SF, Hou Y, Wang P, Zhang W, Pu C, Duan W (2017) Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett 387:77\u201383. https:\/\/doi.org\/10.1016\/j.canlet.2016.03.045. Epub 2016 Apr 1. PMID: 27045474","journal-title":"Cancer Lett"},{"key":"5_CR164","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.omtn.2023.07.009","volume":"33","author":"C Wei","year":"2023","unstructured":"Wei C, Xu Y, Shen Q, Li R, Xiao X, Saw PE, Xu X (2023) Role of long non-coding RNAs in cancer: from subcellular localization to nanoparticle-mediated targeted regulation. Mol Ther Nucleic Acids 33:774\u2013793","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"5_CR165","first-page":"57","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R (2009) Knocking down cancer with RNAi. Nat Rev Drug Discov 8(1):57\u201363","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR166","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA (2021) Noncoding RNA therapeutics \u2014 challenges and potential solutions. Nat Rev Drug Discov 20:629","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5_CR167","doi-asserted-by":"publisher","first-page":"e002938","DOI":"10.1136\/jitc-2021-003928","volume":"10","author":"JE Won","year":"2022","unstructured":"Won JE, Byeon Y, Wi TI, Lee CM, Lee JH, Kang TH, Lee JW, Lee Y, Park YM, Han HD (2022) Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. J Immunother Cancer 10(2):e002938","journal-title":"J Immunother Cancer"},{"issue":"6","key":"5_CR168","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/nat.2012.0389","volume":"22","author":"SC Wong","year":"2012","unstructured":"Wong SC, Klein JJ, Hamilton HL et al (2012) Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther 22(6):380\u2013390","journal-title":"Nucleic Acid Ther"},{"key":"5_CR169","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1158\/0008-5472.CAN-03-2025","volume":"64","author":"Z Xi","year":"2004","unstructured":"Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F (2004) Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64:2365\u20132370","journal-title":"Cancer Res"},{"key":"5_CR170","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/smll.201201510","volume":"9","author":"R Xu","year":"2013","unstructured":"Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H (2013) Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 9:1799\u20131808","journal-title":"Small"},{"key":"5_CR171","doi-asserted-by":"publisher","first-page":"E3553","DOI":"10.1073\/pnas.1412686111","volume":"111","author":"W Xue","year":"2014","unstructured":"Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, Crowley DG, Sahay G, Schroeder A, Langer R, Anderson DG, Jacks T (2014) Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 111:E3553\u2013E3561","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"5_CR172","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-08-0104","volume":"7","author":"Z Yan","year":"2008","unstructured":"Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY (2008) Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther 7(6):1355\u20131364","journal-title":"Mol Cancer Ther"},{"key":"5_CR173","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.cr.7290371","volume":"15","author":"M Yeung","year":"2005","unstructured":"Yeung M, Bennasser Y, Le S et al (2005) siRNA, miRNA and HIV: promises and challenges. Cell Res 15:935\u2013946. https:\/\/doi.org\/10.1038\/sj.cr.7290371","journal-title":"Cell Res"},{"key":"5_CR174","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","volume":"154","author":"S Yonezawa","year":"2020","unstructured":"Yonezawa S, Koide H, Asai T (2020) Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev 154:64\u201378","journal-title":"Adv Drug Deliv Rev"},{"key":"5_CR175","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jconrel.2022.01.012","volume":"342","author":"J Yoon","year":"2022","unstructured":"Yoon J, Shin M, Lee JY, Lee SN, Choi JH, Choi JW (2022) RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy. J Control Release 342:228\u2013240","journal-title":"J Control Release"},{"key":"5_CR176","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jconrel.2014.05.037","volume":"190","author":"J Zhang","year":"2014","unstructured":"Zhang J, Li X, Huang L (2014) Non-viral nanocarriers for siRNA delivery in breast cancer. JControl Release 190:440\u2013450","journal-title":"JControl Release"},{"key":"5_CR177","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2020.1827085","volume":"27","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhao Y, Zhang E, Jiang M, Zhi D, Chen H, Cui S, Zhen Y, Cui J, Zhang S (2020) Co-delivery of paclitaxel and anti-VEGF SiRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy. Drug Deliv 27:1397","journal-title":"Drug Deliv"},{"issue":"D1","key":"5_CR178","doi-asserted-by":"publisher","first-page":"D83","DOI":"10.1093\/nar\/gkab809","volume":"50","author":"W Zhang","year":"2021","unstructured":"Zhang W, Liu Y, Min Z, Liang G, Mo J, Ju Z, Zeng B, Guan W, Zhang Y, Chen J, Zhang Q, Li H, Zeng C, Wei Y, Chan G-F (2021a) Circ- mine: a comprehensive database to integrate, analyze and visualize human disease-related circRNA transcriptome. Nucleic Acids Res 50(D1):D83\u2013D92","journal-title":"Nucleic Acids Res"},{"key":"5_CR179","doi-asserted-by":"publisher","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","volume":"189","author":"MM Zhang","year":"2021","unstructured":"Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB (2021b) The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol 189:114432. https:\/\/doi.org\/10.1016\/j.bcp.2021.114432. Epub 2021 Jan 26. PMID: 33513339; PMCID: PMC8187268","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"5_CR180","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/s41591-022-01997-8","volume":"28","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Vu T, Palmer DC et al (2022) A T cell resilience model associated with response to immunotherapy in multiple tumor types. Nat Med 28(10):2219\u20132219","journal-title":"Nat Med"},{"issue":"5","key":"5_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.822","volume":"12","author":"M Zhou","year":"2022","unstructured":"Zhou M, Zou X, Cheng K et al (2022) The role of cell-penetrating peptides in potential anti-cancer therapy. Clin Transl Med 12(5):e822","journal-title":"Clin Transl Med"},{"key":"5_CR182","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhu L, Wang X et al (2022) RNA-based therapeutics: an overview and prospectus. Cell Death Dis 13:644","journal-title":"Cell Death Dis"},{"issue":"11","key":"5_CR183","first-page":"475","volume":"24","author":"L Ziemer","year":"2017","unstructured":"Ziemer L, Kurrle R (2017) Delivery systems for RNA interference-based cancer therapy. Cancer Gene Ther 24(11):475\u2013484","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"5_CR184","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3390\/ijms23052736","volume":"23","author":"H Zogg","year":"2022","unstructured":"Zogg H, Singh R, Ro S (2022) Current advances in RNA therapeutics for human diseases. Int J Mol Sci 23(5):2736","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5_CR185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211927120","volume":"120","author":"Z Zuo","year":"2023","unstructured":"Zuo Z, Liu J, Sun Z et al (2023) ERK and c-Myc signaling in host-derived tumor endothelial cells is essential for solid tumor growth. Proc Natl Acad Sci USA 120(1):e2211927120","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Experientia Supplementum","Non-coding RNAs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-06948-1_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T01:08:14Z","timestamp":1767316094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-06948-1_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032069474","9783032069481"],"references-count":184,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-06948-1_5","relation":{},"ISSN":["1664-431X","2504-3692"],"issn-type":[{"value":"1664-431X","type":"print"},{"value":"2504-3692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}